Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + vinblastine + doxorubicin + cisplatin + avelumab
- Development stage
- Phase 2
- Lead developer
- Merck KGaA
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This drug combination involves the use of the MVAC chemotherapy regimen (methotrexate, vinblastine, doxorubicin, and cisplatin) followed by avelumab as maintenance therapy. It is primarily used for advanced urothelial carcinoma (aUC). The MVAC component is a long-standing chemotherapy regimen for advanced urothelial carcinoma. The subsequent addition of avelumab as maintenance therapy is a more recent strategy. Clinical trials and real-world data indicate that this combination, particularly with switch maintenance avelumab after dose-dense MVAC (dd-MVAC), significantly improves overall survival and progression-free survival compared to chemotherapy alone or chemotherapy followed by observation. Patients typically receive initial chemotherapy with MVAC (or dd-MVAC), and those who achieve stable disease or better then proceed to maintenance therapy with avelumab to extend the duration of response and improve survival outcomes.
- Other names
- MVAC + avelumabdd-MVAC + avelumab
02
Targets
DNADHFR (Dihydrofolate reductase)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on methotrexate + vinblastine + doxorubicin + cisplatin + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + vinblastine + doxorubicin + cisplatin + avelumab.